U.S. markets close in 1 hour 33 minutes
  • S&P 500

    4,363.81
    -79.30 (-1.78%)
     
  • Dow 30

    34,372.17
    -497.20 (-1.43%)
     
  • Nasdaq

    14,603.56
    -366.41 (-2.45%)
     
  • Russell 2000

    2,235.53
    -45.47 (-1.99%)
     
  • Crude Oil

    75.10
    -0.35 (-0.46%)
     
  • Gold

    1,734.60
    -17.40 (-0.99%)
     
  • Silver

    22.41
    -0.28 (-1.25%)
     
  • EUR/USD

    1.1680
    -0.0022 (-0.19%)
     
  • 10-Yr Bond

    1.5270
    +0.0430 (+2.90%)
     
  • GBP/USD

    1.3527
    -0.0177 (-1.29%)
     
  • USD/JPY

    111.5530
    +0.5750 (+0.52%)
     
  • BTC-USD

    41,498.81
    -1,688.59 (-3.91%)
     
  • CMC Crypto 200

    1,021.98
    -35.16 (-3.33%)
     
  • FTSE 100

    7,028.10
    -35.30 (-0.50%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

CCXI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 6, 2021 in the Class Action Filed on Behalf of ChemoCentryx, Inc. Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York—(Newsfile Corp. - June 22, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ChemoCentryx, Inc. (NASDAQ: CCXI) alleging that the Company violated federal securities laws.

Class Period: November 26, 2019 and May 6, 2021
Lead Plaintiff Deadline: July 6, 2021
No obligation or cost to you.

Learn more about your recoverable losses in CCXI:
http://www.kleinstocklaw.com/pslra-1/chemocentryx-inc-loss-submission-form?id=17096&from=5

ChemoCentryx, Inc. NEWS - CCXI NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that ChemoCentryx, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in ChemoCentryx you have until July 6, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased ChemoCentryx securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the CCXI lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88328